Assessment of pleiotropic and proteinuria reducing effect of irbesartan in chronic kidney disease patients

Not Applicable

Recruiting

• Conditions: Chronic kidney disease stage 1-4

• Registration Number: JPRN-UMIN000002423
• Lead Sponsor: Division of Nephrology Department of Medicine, Showa University School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-09-07
• Study Completion: 2010-12-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients who has past history of adverse effect of taking another ARB 2) Pregnancy 3) Patients who has serious liver disease and coronary heart disease or nephrotic syndrome 4) Judged inappropriate for this study by the physicians

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome is proteinuria reducing effect at four, twelve and twenty-four months after administration of the ARB case compared with at baseline.

Secondary Outcome Measures

Name	Time	Method
The secondary outcome is the impact of irbesartan on adiponectin, leptin, IGF-1, hsCRP, IL-6, IL-10. TNF, at four, twelve and twenty-four months after administration of the ARB case compared with at baseline.